Inactive Instrument

KARA THER

Equities

KRTX

US48576A1007

Delayed Nasdaq 04:00:00 2024-03-15 pm EDT 5-day change 1st Jan Change
329.8 USD +0.03% Intraday chart for KARA THER -.--% +4.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P Biotechnology Select Industry Index CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P TMI Index CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P Global BMI Index CI
Bristol-Myers Squibb Completes Karuna Therapeutics Acquisition MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna MT
Karuna Therapeutics, Inc. and Miramar Merger Sub Inc. Announce Management Changes CI
Bristol Myers: completes acquisition of Karuna Therapeutics CF
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index CI
Bristol-Myers Squibb Company completed the acquisition of Karuna Therapeutics, Inc. from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. and others. CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Biotechnology Index CI
Karuna Therapeutics Q4 Loss Widens MT
Karuna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Karuna Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday MT
Bristol-Myers Squibb's New Product Performance Mixed as Headwinds Persist, Morgan Stanley Says MT
Bristol Myers posts better-than-expected 4th-quarter results RE
North American Morning Briefing : Cautious Start -2- DJ
Mizuho Downgrades Karuna Therapeutics to Neutral From Buy, Raises Price Target to $330 From $245 MT
Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development CI
Karuna Therapeutics Insider Sold Shares Worth $4,752,150, According to a Recent SEC Filing MT
Bristol-Myers Squibb Plans 16 New Products by 2030, CEO says MT
Bristol Myers expects to launch 16 new products through 2030 - CEO RE
Deutsche Bank Downgrades Karuna Therapeutics to Hold From Buy, Adjusts Price Target to $330 From $227 MT
UBS Raises Price Target on Karuna Therapeutics to $330 From $197, Keeps Neutral Rating MT
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close DJ
Chart KARA THER
More charts
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. KRTX Stock
  4. News KARA THER
  5. Karuna Therapeutics Q4 Loss Widens